BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window of opportunity to develop drug candidates toward known targets with known mechanisms of actions that would allow it to become first-in-class in China. But how well would the company's strategy hold up to the 2017 regulatory reforms?

【書誌情報】

ページ数：12ページ

サイズ：A4

商品番号：HBSP-618033

発行日：2017/11/13

登録日：2018/3/15